Kelly Pladson - Entheon Biomedical Co Sec
| ENTBF Stock | USD 0.12 0.03 33.33% |
Insider
Kelly Pladson is Co Sec of Entheon Biomedical Corp
| Age | 40 |
| Phone | 604-562-3932 |
| Web | https://www.entheonbiomedical.com |
Entheon Biomedical Management Efficiency
The company has return on total asset (ROA) of (0.4631) % which means that it has lost $0.4631 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5469) %, meaning that it generated substantial loss on money invested by shareholders. Entheon Biomedical's management efficiency ratios could be used to measure how well Entheon Biomedical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | INSIDER Age | ||
| Simon Beaudoin | Defence Therapeutics | 39 | |
| Sebastien Plouffe | Defence Therapeutics | 51 | |
| Oren Hershkovitz | Enlivex Therapeutics | 47 | |
| Shachar CPA | Enlivex Therapeutics | 47 | |
| Sigal Arad | Enlivex Therapeutics | N/A | |
| Carrie Cesarone | Defence Therapeutics | 58 | |
| Pr MD | Enlivex Therapeutics | 68 | |
| Eric Tse | Sino Biopharmaceutical Ltd | 27 | |
| Moutih Rafei | Defence Therapeutics | 41 | |
Management Performance
| Return On Equity | -0.55 | |||
| Return On Asset | -0.46 |
Entheon Biomedical Corp Leadership Team
Elected by the shareholders, the Entheon Biomedical's board of directors comprises two types of representatives: Entheon Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Entheon. The board's role is to monitor Entheon Biomedical's management team and ensure that shareholders' interests are well served. Entheon Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Entheon Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kelly Pladson, Co Sec | ||
| Andrew Hegle, Director Officer | ||
| Timothy Ko, CEO Pres | ||
| CGA CPA, Chief Officer | ||
| Brian PharmD, Chief Officer |
Entheon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Entheon Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.55 | |||
| Return On Asset | -0.46 | |||
| Operating Margin | (60.27) % | |||
| Current Valuation | 1.12 M | |||
| Shares Outstanding | 59.09 M | |||
| Shares Owned By Insiders | 8.63 % | |||
| Price To Book | 0.22 X | |||
| Price To Sales | 9.60 X | |||
| Revenue | 21.67 K | |||
| Gross Profit | 9.13 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Entheon OTC Stock
Entheon Biomedical financial ratios help investors to determine whether Entheon OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Entheon with respect to the benefits of owning Entheon Biomedical security.